Status:

COMPLETED

FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging

Lead Sponsor:

Columbia University

Collaborating Sponsors:

Centers for Disease Control and Prevention

Conditions:

Fever

Eligibility:

All Genders

6-23 years

Brief Summary

In this study, the investigators will prospectively assess fever rates and other associated vaccine adverse events in 6-23 month old patients during days 0-7 after administration of trivalent inactiva...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • are 6 through 23 month olds,
  • have a visit at a study site during the study period of Nov. 1, 2011 through March 31, 2012,
  • receive trivalent inactivated influenza vaccine (TIV)/13-valent pneumococcal conjugate vaccine (PCV13)concomitantly, trivalent inactivated influenza vaccine (TIV)/without 13-valent pneumococcal conjugate vaccine (PCV13) or 13-valent pneumococcal conjugate vaccine (PCV13) without trivalent inactivated influenza vaccine (TIV)/(4) parent has a cell phone with text messaging capabilities; and
  • (5) parent speaks English or Spanish.
  • Exclusion criteria:
  • presence of fever \>=100.4 at time of vaccination;
  • administration of any antipyretic in the 6-hour period prior to vaccination
  • stated intent to use prophylactic antipyretics at time of vaccination before the development of a fever;
  • stated intention to move away from the NYC area \<6 month;
  • parent only speaks a language other than English or Spanish;
  • inability to read text messages;
  • children who received live attenuated influenza vaccine (LAIV) this visit;
  • children who received trivalent inactivated influenza vaccine (TIV) or 13-valent pneumococcal conjugate vaccine (PCV13) in the seven days prior to enrollment date
  • Note: Patient may receive other vaccines in addition to trivalent inactivated influenza vaccine (TIV)/13-valent pneumococcal conjugate vaccine (PCV13)

Exclusion

    Key Trial Info

    Start Date :

    November 1 2011

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    June 1 2012

    Estimated Enrollment :

    530 Patients enrolled

    Trial Details

    Trial ID

    NCT01467934

    Start Date

    November 1 2011

    End Date

    June 1 2012

    Last Update

    July 21 2014

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Centers for Disease Control and Prevention

    Atlanta, Georgia, United States, 30333

    2

    Columbia University

    New York, New York, United States, 10032